Travere Therapeutics, Inc. $TVTX reported second-quarter 2026 revenue of $169.6 million, up 48.2% from a year earlier and above the $162.8 million consensus estimate. Gross profit rose in step with sales to $167.4 million, underscoring continued top-line momentum for the biotech company.
Profitability remained mixed. Operating profit came in at $4.0 million, while net loss attributable to common shareholders narrowed to $34.8 million, or ($0.37) per diluted share. That compared with a smaller loss expected by analysts, but the company still posted a bottom-line deficit for the quarter.
Cash generation improved sharply, with operating cash flow reaching $58.1 million versus a much lower level a year ago. Travere ended the period with $117.7 million in cash and cash equivalents, while total liabilities stood at $774.8 million.
- Revenue: $169.6 million
- Gross profit: $167.4 million
- Operating cash flow: $58.1 million
- Net loss: ($34.8 million)
- Diluted EPS: ($0.37)
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Travere Therapeutics, Inc. Insider Trading Activity
Travere Therapeutics, Inc. insiders have traded $TVTX stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.
Here’s a breakdown of recent trading of $TVTX stock by insiders over the last 6 months:
- ERIC M DUBE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 9 sales selling 306,587 shares for an estimated $10,510,770.
- ELIZABETH E REED (Chief Legal Officer and GC) has made 0 purchases and 14 sales selling 115,919 shares for an estimated $4,405,104.
- ROY D. BAYNES has made 0 purchases and 6 sales selling 61,500 shares for an estimated $2,548,200.
- JULA INRIG (CHIEF MEDICAL OFFICER) has made 0 purchases and 8 sales selling 39,453 shares for an estimated $1,641,700.
- SANDRA CALVIN (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 2 sales selling 26,310 shares for an estimated $1,041,771.
- WILLIAM E. ROTE (Chief Research Officer) has made 0 purchases and 3 sales selling 24,309 shares for an estimated $886,252.
- CHRISTOPHER R. CLINE (CHIEF FINANCIAL OFFICER) has made 0 purchases and 9 sales selling 19,805 shares for an estimated $753,123.
- PETER HEERMA (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 3 sales selling 16,699 shares for an estimated $638,730.
- TIMOTHY COUGHLIN sold 10,000 shares for an estimated $500,747
- JEFFREY A MECKLER sold 8,000 shares for an estimated $360,000
- GARY A LYONS sold 8,000 shares for an estimated $328,560
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Travere Therapeutics, Inc. Hedge Fund Activity
We have seen 143 institutional investors add shares of Travere Therapeutics, Inc. stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,575,000 shares (-72.5%) from their portfolio in Q1 2026, for an estimated $76,503,250
- FMR LLC added 1,350,104 shares (+14.0%) to their portfolio in Q1 2026, for an estimated $40,111,589
- ARMISTICE CAPITAL, LLC added 1,133,526 shares (+30.1%) to their portfolio in Q1 2026, for an estimated $33,677,057
- MPM BIOIMPACT LLC added 1,133,365 shares (+inf%) to their portfolio in Q1 2026, for an estimated $33,672,274
- MORGAN STANLEY removed 1,114,242 shares (-78.7%) from their portfolio in Q1 2026, for an estimated $33,104,129
- KYNAM CAPITAL MANAGEMENT, LP added 1,051,134 shares (+203.0%) to their portfolio in Q1 2026, for an estimated $31,229,191
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 753,354 shares (-86.8%) from their portfolio in Q1 2026, for an estimated $22,382,147
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Travere Therapeutics, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TVTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 06/03/2026
To track analyst ratings and price targets for Travere Therapeutics, Inc., check out Quiver Quantitative's $TVTX forecast page.
Travere Therapeutics, Inc. Price Targets
Multiple analysts have issued price targets for $TVTX recently. We have seen 10 analysts offer price targets for $TVTX in the last 6 months, with a median target of $60.5.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $65.0 on 06/25/2026
- Laura Chico from Wedbush set a target price of $61.0 on 06/22/2026
- Liisa Bayko from Evercore ISI Group set a target price of $60.0 on 06/18/2026
- Yigal Nochomovitz from Citigroup set a target price of $70.0 on 06/15/2026
- Mohit Bansal from Wells Fargo set a target price of $65.0 on 06/12/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $67.0 on 06/02/2026
- Tyler Van Buren from TD Cowen set a target price of $60.0 on 05/05/2026
